BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Motyl AAL, Faller KME, Groen EJN, Kline RA, Eaton SL, Ledahawsky LM, Chaytow H, Lamont DJ, Wishart TM, Huang YT, Gillingwater TH. Pre-natal manifestation of systemic developmental abnormalities in spinal muscular atrophy. Hum Mol Genet 2020;29:2674-83. [PMID: 32644120 DOI: 10.1093/hmg/ddaa146] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Finkel RS, Lorson CL. Friend or Foe(tal): challenges in development of a large animal model for pre-clinical fetal gene therapy. Gene Ther 2022. [PMID: 35256766 DOI: 10.1038/s41434-022-00327-4] [Reference Citation Analysis]
2 Rossoll W, Singh RN. Commentary: Current Status of Gene Therapy for Spinal Muscular Atrophy. Front Cell Neurosci 2022;16:916065. [DOI: 10.3389/fncel.2022.916065] [Reference Citation Analysis]
3 Singh NN, Hoffman S, Reddi PP, Singh RN. Spinal muscular atrophy: Broad disease spectrum and sex-specific phenotypes. Biochim Biophys Acta Mol Basis Dis 2021;1867:166063. [PMID: 33412266 DOI: 10.1016/j.bbadis.2020.166063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Chaytow H, Faller KME, Huang YT, Gillingwater TH. Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine. Cell Rep Med 2021;2:100346. [PMID: 34337562 DOI: 10.1016/j.xcrm.2021.100346] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Faravelli I, Corti S. Spinal muscular atrophy - challenges in the therapeutic era. Nat Rev Neurol 2020;16:655-6. [PMID: 32918067 DOI: 10.1038/s41582-020-00411-6] [Reference Citation Analysis]
6 Reilly A, Chehade L, Kothary R. Curing SMA: Are we there yet? Gene Ther 2022. [PMID: 35614235 DOI: 10.1038/s41434-022-00349-y] [Reference Citation Analysis]
7 Singh RN, Ottesen EW, Singh NN. The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy. Neurosci Insights 2020;15:2633105520973985. [PMID: 33283185 DOI: 10.1177/2633105520973985] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
8 Deguise MO, Chehade L, Kothary R. Metabolic Dysfunction in Spinal Muscular Atrophy. Int J Mol Sci 2021;22:5913. [PMID: 34072857 DOI: 10.3390/ijms22115913] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wirth B. Spinal Muscular Atrophy: In the Challenge Lies a Solution. Trends Neurosci 2021;44:306-22. [PMID: 33423791 DOI: 10.1016/j.tins.2020.11.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
10 Detering NT, Zambon A, Hensel N, Kothary R, Swoboda K, Gillingwater TH, Baranello G. 264th ENMC International Workshop: Multi-system involvement in Spinal Muscular Atrophy Hoofddorp, The Netherlands, November 19th – 21th 2021. Neuromuscular Disorders 2022. [DOI: 10.1016/j.nmd.2022.06.005] [Reference Citation Analysis]
11 Varderidou-Minasian S, Verheijen BM, Harschnitz O, Kling S, Karst H, van der Pol WL, Pasterkamp RJ, Altelaar M. Spinal Muscular Atrophy Patient iPSC-Derived Motor Neurons Display Altered Proteomes at Early Stages of Differentiation. ACS Omega 2021;6:35375-88. [PMID: 34984269 DOI: 10.1021/acsomega.1c04688] [Reference Citation Analysis]